First Subject Enrolled in Phase II/III Study of Eisai’s Anti-MTBR Tau Antibody E2814 for Dominantly Inherited Alzheimer’s Disease (DIAD), conducted by DIAN-TU (Links to an external site)
New Alzheimer’s prevention trial in young people (Links to an external site)
$11.5 million commitment supports new Alzheimer’s prevention clinical trial (Links to an external site)
New eligibility criteria for participation in Tau NexGen E2814: A requirement for participants to learn their genetic status prior to enrollment
The new Tau NexGen E2814 clinical trial planned for DIAN-TU will be launching at most sites in 2022. This new trial design will offer individuals who have a dominantly inherited Alzheimer’s disease (DIAD) mutation access to investigational drugs that target both amyloid and tau. All participants will receive the anti-amyloid drug and also be randomized […]
International Alzheimer’s clinical trial to test two drugs in combination (Links to an external site)
Global Incubator Seed Grants awarded (Links to an external site)
The Search for a Drug to End Alzheimer’s (Links to an external site)
Some antiamyloids remove target plaques from the brain, yet don’t seem to halt cognitive decline. Researchers are working to understand why.
Aiming at the Tangle’s Heart? DIAN-TU Trial to Torpedo Tau’s Core (Links to an external site)
Encouraging findings in Alzheimer’s prevention trial lead to the next phase (Links to an external site)
International Alzheimer’s clinical trial to test tau drugs (Links to an external site)
Bateman, Diamond, Hultgren named to National Academy of Inventors (Links to an external site)
School of Medicine scientists honored for innovation
Dementia First blood test to help diagnose Alzheimer’s goes on sale (Links to an external site)
Barch, Bateman elected to National Academy of Medicine (Links to an external site)
AAIC 2020, dallo studio DIAN-TU la terapia contro l’Alzheimer (Links to an external site)
Elixir Factor Podcast S2 Ep6: Dominantly Inherited Alzheimer’s Disease: A View From Within (Links to an external site)
Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned (Links to an external site)
Confused About the DIAN-TU Trial Data? Experts Discuss Nuances (Links to an external site)
Topline Result for First DIAN-TU Clinical Trial: Negative on Primary (Links to an external site)
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
Top-line data reported from international trial
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
A message from Dr. Bateman to DIAN-TU trial participants
Video
DIAN-TU Mcdade: “Nel 2020 sapremo se possiamo bloccare l’Alzheimer” (Links to an external site)
Importante estudio en enfermedad de Alzheimer abrirá 5 nuevos sitios latinoamericanos (Links to an external site)
Major Alzheimer’s study to open 5 new Latin American sites (Links to an external site)
Why Didn’t She Get Alzheimer’s? The Answer Could Hold a Key to Fighting the Disease (Links to an external site)
‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab (Links to an external site)
Wash U leading worldwide Alzheimer’s study (Links to an external site)
The importance of prevention trials in Alzheimer’s disease with Randall Bateman (Links to an external site)
Blood test is highly accurate at identifying Alzheimer’s before symptoms arise (Links to an external site)
